Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last decade, PPAR-γ agonists have received increasing attention for their neuroprotective properties displayed in a varie...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.4061/2011/689181 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|